BRIACELL THERAPEUTICS CORP (BCTX) Stock Price, Quote, News and Overview
NASDAQ:BCTX - Nasdaq - CA1079302081 - Common Stock - Currency: USD
BCTX Quote, Performance and Key Statistics
5.2
-0.83 (-13.76%)
The current stock price of BCTX is 5.2 USD. In the past month the price increased by 28.71%. In the past year, price decreased by -84.02%.
BCTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.12 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 323.56 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About BCTX
Company Profile
Briacell Therapeutics Corp is a CA-based company operating in Biotechnology industry. The company is headquartered in West Vancouver, British Columbia and currently employs 17 full-time employees. The company went IPO on 2006-10-12. BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Company Info
BRIACELL THERAPEUTICS CORP
Suite 300 - Bellevue Centre, 235 -15th Street
West Vancouver BRITISH COLUMBIA V7T 2X1 CA
CEO: William V. Williams
Employees: 16
Company Website: https://briacell.com/
Investor Relations: http://investors.briacell.com/filings-and-shareholder-info
Phone: 16049211810
BRIACELL THERAPEUTICS CORP / BCTX FAQ
What is the stock price of BRIACELL THERAPEUTICS CORP today?
The current stock price of BCTX is 5.2 USD. The price decreased by -13.76% in the last trading session.
What is the ticker symbol for BRIACELL THERAPEUTICS CORP stock?
The exchange symbol of BRIACELL THERAPEUTICS CORP is BCTX and it is listed on the Nasdaq exchange.
On which exchange is BCTX stock listed?
BCTX stock is listed on the Nasdaq exchange.
What is BRIACELL THERAPEUTICS CORP worth?
BRIACELL THERAPEUTICS CORP (BCTX) has a market capitalization of 19.29M USD. This makes BCTX a Nano Cap stock.
How many employees does BRIACELL THERAPEUTICS CORP have?
BRIACELL THERAPEUTICS CORP (BCTX) currently has 16 employees.
What are the support and resistance levels for BRIACELL THERAPEUTICS CORP (BCTX) stock?
BRIACELL THERAPEUTICS CORP (BCTX) has a support level at 3.95. Check the full technical report for a detailed analysis of BCTX support and resistance levels.
Should I buy BRIACELL THERAPEUTICS CORP (BCTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BCTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BCTX, evaluating the profitability, health, valuation and growth aspects
- BRIACELL THERAPEUTICS CORP (BCTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BRIACELL THERAPEUTICS CORP (BCTX) Sales and EPS estimates to see what analysts future expectations are.
- BRIACELL THERAPEUTICS CORP (BCTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BRIACELL THERAPEUTICS CORP (BCTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BRIACELL THERAPEUTICS CORP (BCTX) Stock Chart to make your own analysis
- BRIACELL THERAPEUTICS CORP (BCTX) Latest news and press-releases to stay up to date.
Does BRIACELL THERAPEUTICS CORP (BCTX) stock pay dividends?
BCTX does not pay a dividend.
When does BRIACELL THERAPEUTICS CORP (BCTX) report earnings?
BRIACELL THERAPEUTICS CORP (BCTX) will report earnings on 2025-06-12.
What is the Price/Earnings (PE) ratio of BRIACELL THERAPEUTICS CORP (BCTX)?
BRIACELL THERAPEUTICS CORP (BCTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.57).
What is the Short Interest ratio of BRIACELL THERAPEUTICS CORP (BCTX) stock?
The outstanding short interest for BRIACELL THERAPEUTICS CORP (BCTX) is 5.55% of its float. Check the ownership tab for more information on the BCTX short interest.
BCTX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to BCTX. When comparing the yearly performance of all stocks, BCTX is a bad performer in the overall market: 92.49% of all stocks are doing better.
BCTX Financial Highlights
Over the last trailing twelve months BCTX reported a non-GAAP Earnings per Share(EPS) of -6.57. The EPS decreased by -293.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -197.4% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BCTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to BCTX. The Buy consensus is the average rating of analysts ratings from 5 analysts.